Detalhe da pesquisa
1.
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
Blood
; 140(26): 2773-2787, 2022 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126318
2.
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry.
Haematologica
; 2024 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572549
3.
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry.
Hematol Oncol
; 42(1): e3240, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38050405
4.
Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach.
Int J Mol Sci
; 25(7)2024 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38612443
5.
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
Blood
; 139(10): 1588-1592, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34748627
6.
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Infection
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388854
7.
Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Infection
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771466
8.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222267
9.
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.
Am J Hematol
; 97(8): E312-E317, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35702878
10.
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
Leuk Lymphoma
; 65(2): 199-208, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966980
11.
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.
EClinicalMedicine
; 71: 102553, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38533127
12.
A Rare Case of Hodgkin Lymphoma of the Maxillary Sinus.
Ear Nose Throat J
; 102(5): NP232-NP236, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33734885
13.
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Ther Adv Hematol
; 14: 20406207231154706, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36923264
14.
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.
Front Immunol
; 14: 1125030, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36911708
15.
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
J Hematol Oncol
; 16(1): 32, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005697
16.
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.
EClinicalMedicine
; 58: 101939, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37041967
17.
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
Int J Antimicrob Agents
; 62(4): 106952, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37582478
18.
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings.
Int J Infect Dis
; 137: 98-110, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37863310
19.
SF3B1 Mutations in Hematological Malignancies.
Cancers (Basel)
; 14(19)2022 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230848
20.
Detection of SF3B1 p.Lys700Glu Mutation by PNA-PCR Clamping in Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
J Clin Med
; 11(5)2022 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35268357